These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 16289887)

  • 1. Mapping brain activity following administration of a nicotinic acetylcholine receptor agonist, ABT-594, using functional magnetic resonance imaging in awake rats.
    Skoubis PD; Hradil V; Chin CL; Luo Y; Fox GB; McGaraughty S
    Neuroscience; 2006; 137(2):583-91. PubMed ID: 16289887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological MRI in awake rats predicts selective binding of alpha4beta2 nicotinic receptors.
    Chin CL; Pauly JR; Surber BW; Skoubis PD; McGaraughty S; Hradil VP; Luo Y; Cox BF; Fox GB
    Synapse; 2008 Mar; 62(3):159-68. PubMed ID: 18081183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.
    Zhu CZ; Chin CL; Rustay NR; Zhong C; Mikusa J; Chandran P; Salyers A; Gomez E; Simler G; Lewis LG; Gauvin D; Baker S; Pai M; Tovcimak A; Brown J; Komater V; Fox GB; Decker MW; Jacobson PB; Gopalakrishnan M; Lee CH; Honore P
    Biochem Pharmacol; 2011 Oct; 82(8):967-76. PubMed ID: 21620806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.
    Bannon AW; Decker MW; Curzon P; Buckley MJ; Kim DJ; Radek RJ; Lynch JK; Wasicak JT; Lin NH; Arnold WH; Holladay MW; Williams M; Arneric SP
    J Pharmacol Exp Ther; 1998 May; 285(2):787-94. PubMed ID: 9580627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model.
    Lynch JJ; Wade CL; Mikusa JP; Decker MW; Honore P
    Eur J Pharmacol; 2005 Feb; 509(1):43-8. PubMed ID: 15713428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain.
    Joshi SK; Mikusa JP; Weaver B; Honore P
    J Pain; 2008 Feb; 9(2):146-56. PubMed ID: 18088559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antinociceptive effects of centrally administered CDP-choline on acute pain models in rats: the involvement of cholinergic system.
    Hamurtekin E; Gurun MS
    Brain Res; 2006 Oct; 1117(1):92-100. PubMed ID: 16942753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High resolution spatial mapping of nicotine action using pharmacologic magnetic resonance imaging.
    Choi JK; Mandeville JB; Chen YI; Kim YR; Jenkins BG
    Synapse; 2006 Aug; 60(2):152-7. PubMed ID: 16715493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological MRI in awake rats reveals neural activity in area postrema and nucleus tractus solitarius: relevance as a potential biomarker for detecting drug-induced emesis.
    Chin CL; Fox GB; Hradil VP; Osinski MA; McGaraughty SP; Skoubis PD; Cox BF; Luo Y
    Neuroimage; 2006 Dec; 33(4):1152-60. PubMed ID: 17023182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys.
    Buccafusco JJ; Terry AV; Decker MW; Gopalakrishnan M
    Biochem Pharmacol; 2007 Oct; 74(8):1202-11. PubMed ID: 17706609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist.
    Rao TS; Adams PB; Correa LD; Santori EM; Sacaan AI; Reid RT; Cosford ND
    Brain Res; 2008 Oct; 1234():16-24. PubMed ID: 18692487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-resolution functional magnetic resonance imaging of the rat brain: mapping changes in cerebral blood volume using iron oxide contrast media.
    van Bruggen N; Busch E; Palmer JT; Williams SP; de Crespigny AJ
    J Cereb Blood Flow Metab; 1998 Nov; 18(11):1178-83. PubMed ID: 9809506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats.
    Levin ED; Rezvani AH; Xiao Y; Slade S; Cauley M; Wells C; Hampton D; Petro A; Rose JE; Brown ML; Paige MA; McDowell BE; Kellar KJ
    J Pharmacol Exp Ther; 2010 Mar; 332(3):933-9. PubMed ID: 20007754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of functional neuronal nicotinic receptors in dorsal root ganglion neurons in a rat model of neuropathic pain.
    Dubé GR; Kohlhaas KL; Rueter LE; Surowy CS; Meyer MD; Briggs CA
    Neurosci Lett; 2005 Mar; 376(1):29-34. PubMed ID: 15694269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects.
    Mohler EG; Franklin SR; Rueter LE; Fox GB; Decker MW; Browman KE
    Pharmacol Biochem Behav; 2010 Apr; 95(2):146-57. PubMed ID: 20064548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine.
    Vann RE; Rosecrans JA; James JR; Philibin SD; Robinson SE
    Brain Res; 2006 Oct; 1117(1):18-24. PubMed ID: 16949560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice.
    Decker MW; Bannon AW; Buckley MJ; Kim DJ; Holladay MW; Ryther KB; Lin NH; Wasicak JT; Williams M; Arneric SP
    Eur J Pharmacol; 1998 Apr; 346(1):23-33. PubMed ID: 9617748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain.
    Lee CH; Zhu C; Malysz J; Campbell T; Shaughnessy T; Honore P; Polakowski J; Gopalakrishnan M
    Biochem Pharmacol; 2011 Oct; 82(8):959-66. PubMed ID: 21763685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional responses and subunit composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-A-85380.
    Mogg AJ; Jones FA; Pullar IA; Sharples CG; Wonnacott S
    Neuropharmacology; 2004 Nov; 47(6):848-59. PubMed ID: 15527819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A-186253, a specific antagonist of the alpha 4 beta 2 nAChRs: its properties and potential to study brain nicotinic acetylcholine receptors.
    Itier V; Schönbächler R; Tribollet E; Honer M; Prinz K; Marguerat A; Bertrand S; Bunnelle WH; Schubiger PA; Meyer MD; Sullivan JP; Bertrand D; Westera G
    Neuropharmacology; 2004 Sep; 47(4):538-57. PubMed ID: 15380372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.